Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

EUROPEAN MARKETING AUTHORIZATION APPLICATION ON TRACK IN 2H25   PREVAIL PHASE 3 CVOT REMAINS ON TRACK   LATE BREAKING BROADWAY AND TANDEM DATA PRESENTED AT EAS 2025 AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE (BROADWAY) AND THE LANCET (TANDEM)   BROADWAY ALZHEIMER'S DISEASE ANALYSIS PRESENTED AT AAIC 2025 SHOWED OBICETRAPIB SIGNIFICANTLY REDUCED PLASMA P-TAU217 LEVELS VERSUS PLACEBO IN BOTH THE FULL ANALYSIS SET AND IN APOE4 CARRIERS, OVER 12 MONTHS, WITH FAVORABLE TRENDS OBSERVED IN ADDITIONAL ALZHEIMER'S BIOMARKERS  NAARDEN, THE NETHERLANDS AND MIAMI, AUG. 06, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025 AND PROVIDED A CORPORATE UPDATE.

NEWAMSTERDAM PHARMA PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER FINANCIAL RESULTS

-- PRE-SPECIFIED ANALYSIS SHOWS OBICETRAPIB SIGNIFICANTLY REDUCED ABSOLUTE LEVELS OF PLASMA P-TAU217, A KEY BIOMARKER OF ALZHEIMER'S DISEASE PATHOLOGY, IN BOTH THE FULL ANALYSIS SET (P=0.0019) AND IN APOE4 CARRIERS (P=0.0215), SUPPORTING CETP INHIBITION AS A POTENTIAL NOVEL, UPSTREAM APPROACH TO ALZHEIMER'S PREVENTION 

NEWAMSTERDAM PHARMA PRESENTS POSITIVE DATA FROM BROADWAY TRIAL DEMONSTRATING STATISTICALLY SIGNIFICANT REDUCTIONS IN KEY ALZHEIMER'S DISEASE BIOMARKERS AT AAIC 2025

NAARDEN, THE NETHERLANDS AND MIAMI, JULY 22, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT IT WILL PRESENT FULL DATA FROM THE PRESPECIFIED ALZHEIMER'S DISEASE (AD) BIOMARKER ANALYSES IN THE BROADWAY CLINICAL TRIAL (NCT05142722) IN A LATE-BREAKING ORAL PRESENTATION AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC), BEING HELD JULY 30, 2025 IN TORONTO, CANADA.

NEWAMSTERDAM PHARMA TO PRESENT ALZHEIMER'S BIOMARKER DATA FROM BROADWAY TRIAL AT AAIC 2025

-- PRE-SPECIFIED ANALYSES SHOW THAT OBICETRAPIB TREATMENT LEADS TO STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL REDUCTIONS IN THE PRIMARY OUTCOME MEASURE OF ALZHEIMER'S DISEASE BIOMARKER IN BOTH THE FULL ITT POPULATION (P

NEWAMSTERDAM PHARMA ANNOUNCES POSITIVE TOPLINE ALZHEIMER'S DISEASE DATA FROM BROADWAY CLINICAL TRIAL

NAARDEN, THE NETHERLANDS AND MIAMI, JUNE 05, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT IT WILL HOST AN R&D DAY EVENT FOR ANALYSTS AND INVESTORS ON JUNE 11, 2025 BEGINNING AT 9:00 A.M.

NEWAMSTERDAM PHARMA TO HOST R&D DAY ON JUNE 11, 2025

NAARDEN, THE NETHERLANDS AND MIAMI, MAY 27, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

NEWAMSTERDAM PHARMA TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES IN JUNE

NAARDEN, THE NETHERLANDS AND MIAMI, MAY 14, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT IAN SOMAIYA, CHIEF FINANCIAL OFFICER OF NEWAMSTERDAM PHARMA, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 2025 RBCCM GLOBAL HEALTHCARE CONFERENCE ON TUESDAY, MAY 20, 2025 AT 10:00 A.M.

NEWAMSTERDAM PHARMA TO PRESENT AT THE 2025 RBCCM GLOBAL HEALTHCARE CONFERENCE

 EMA SUBMISSION EXPECTED IN 2H25 BY PARTNER MENARINI   PREVAIL PHASE 3 CVOT REMAINS ON TRACK  -- BROADWAY AND TANDEM RESULTS PRESENTED AT EAS WITH SIMULTANEOUS PUBLICATIONS IN THE NEW ENGLAND JOURNAL OF MEDICINE AND THE LANCET, RESPECTIVELY -- -- COMPANY TO HOST R&D DAY ON JUNE 11 TH , 2025 IN NEW YORK CITY -- $808.5 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT MARCH 31, 2025  NAARDEN, THE NETHERLANDS AND MIAMI, MAY 08, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM, WE, OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2025 AND PROVIDED A CORPORATE UPDATE.

NEWAMSTERDAM PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER FINANCIAL RESULTS

 LATE BREAKING BROADWAY AND TANDEM DATA PRESENTED AT EAS 2025 AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE (BROADWAY) AND THE LANCET (TANDEM) 

NEWAMSTERDAM PHARMA ANNOUNCES LATE-BREAKING DATA FROM BROADWAY AND TANDEM PIVOTAL STUDIES PUBLISHED IN LEADING MEDICAL JOURNALS AND PRESENTED AT THE EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) CONGRESS 2025

NAARDEN, THE NETHERLANDS AND MIAMI, MAY 02, 2025 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF NEWAMSTERDAM'S BOARD OF DIRECTORS APPROVED THE GRANT OF INDUCEMENT SHARE OPTIONS COVERING AN AGGREGATE OF 197,000 OF NEWAMSTERDAM'S ORDINARY SHARES TO ELEVEN NON-EXECUTIVE NEW HIRES. THE SHARE OPTIONS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE EMPLOYEES' ACCEPTANCE OF EMPLOYMENT WITH NEWAMSTERDAM PURSUANT TO THE NEWAMSTERDAM PHARMA COMPANY N.V. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN) AND IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

NewAmsterdam Pharma Company N.V.

NAMS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NewAmsterdam Pharma Company N.V.

NAMS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NAMS